These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 12762505)
1. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF. Wadhwa M; Mellstedt H; Small E; Thorpe R Dev Biol (Basel); 2003; 112():61-7. PubMed ID: 12762505 [TBL] [Abstract][Full Text] [Related]
2. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Ragnhammar P; Wadhwa M Med Oncol; 1996 Sep; 13(3):161-6. PubMed ID: 9106175 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919 [TBL] [Abstract][Full Text] [Related]
4. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M Clin Immunol; 2001 Apr; 99(1):65-74. PubMed ID: 11286542 [TBL] [Abstract][Full Text] [Related]
5. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439 [TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome. Hellmich B; Ciaglo A; Schatz H; Coakley G Ann Rheum Dis; 2004 Jul; 63(7):862-6. PubMed ID: 15194585 [TBL] [Abstract][Full Text] [Related]
7. Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques. Eisenblätter M; Stahl-Hennig C; Kuate S; Stolte N; Jasny E; Hahn H; Pope M; Tenner-Racz K; Racz P; Steinman RM; Uberla K; Ignatius R Vaccine; 2004 Sep; 22(25-26):3295-302. PubMed ID: 15308352 [TBL] [Abstract][Full Text] [Related]
8. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433 [TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714 [TBL] [Abstract][Full Text] [Related]
10. [Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis]. Xu KF; Chen Y; Guo ZJ; Zhu YJ Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):824-8. PubMed ID: 15730782 [TBL] [Abstract][Full Text] [Related]
11. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695 [TBL] [Abstract][Full Text] [Related]
14. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Latzin P; Tredano M; Wüst Y; de Blic J; Nicolai T; Bewig B; Stanzel F; Köhler D; Bahuau M; Griese M Thorax; 2005 Jan; 60(1):39-44. PubMed ID: 15618581 [TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
16. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
17. Macrophage-colony stimulating factor is required for the production of neutrophil-promoting activity by mouse embryo fibroblasts deficient in G-CSF and GM-CSF. Zhang HH; Basu S; Wu F; Begley CG; Saris CJ; Dunn AR; Burgess AW; Walker F J Leukoc Biol; 2007 Oct; 82(4):915-25. PubMed ID: 17652450 [TBL] [Abstract][Full Text] [Related]